pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Sep 14·1 min read
save

Opinion: Restoring public trust in science requires humility and collaboration, not just better messaging

Sep 14, 2026·read at STAT ↗Neutral

Michelle Groman and Caroline Montojo, presidents of The Greenwall Foundation and the Dana Foundation, wrote an opinion piece on Sept. 14, 2026 about the challenge of rebuilding public trust in science.

They note that discussions often split between those who think improved communication will solve the problem and those who believe the issue is too large to address directly. The authors question whether scientists and the public share a common definition of "trust" and whether messaging alone can bridge the gap.

The piece points out that surveys still show overall trust in science remains reasonably high, yet public opinion is increasingly polarized and often diverges from scientific consensus. The authors argue that focusing solely on headlines and statistics misses the deeper relational work needed.

Groman and Montojo conclude that restoring trust calls for humility, a broad perspective, and collaboration across disciplines, rather than a simple messaging fix.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: Restoring public trust in science doesn’t have a simple solution. That’s OK”

read at STAT ↗
1,303 words · retrieved Sep 14
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADINGPATHSilo Pharma, Inc.Ultragenyx Pharmaceutical Inc.University of California Los Angeles
topics
Rare DiseaseVaccine

related stories

  • 5h agoTeva closing New Jersey manufacturing facility, laying off 61 employeesBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Apr 24Opinion: I started medical school at 69 and will begin residency at 72. Here’s what I learnedSTAT
  • Dec 22Fierce Biotech Fundraising Tracker '26: Nouscom nabs $135M series D; Estuary channels $93M series AFierce Biotech
  • Jul 27After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaborationFierce Biotech